title: Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study.
abstract: BACKGROUND
  The control arm of PATRICIA (PApilloma TRIal against Cancer In young Adults, NCT00122681) was used to investigate the risk of progression from cervical HPV infection to cervical intraepithelial neoplasia (CIN) or clearance of infection, and associated determinants.
  
  
  RESULTS
  Women aged 15-25 years were enrolled. A 6-month persistent HPV infection (6MPI) was defined as detection of the same HPV type at two consecutive evaluations over 6 months and clearance as ≥2 type-specific HPV negative samples taken at two consecutive intervals of approximately 6 months following a positive sample. The primary endpoint was CIN grade 2 or greater (CIN2+) associated with the same HPV type as a 6MPI. Secondary endpoints were CIN1+/CIN3+ associated with the same HPV type as a 6MPI; CIN1+/CIN2+/CIN3+ associated with an infection of any duration; and clearance of infection. The analyses included 4825 women with 16,785 infections (3363 women with 6902 6MPIs). Risk of developing a CIN1+/CIN2+/CIN3+ associated with same HPV type as a 6MPI varied with HPV type and was significantly higher for oncogenic versus non-oncogenic types. Hazard ratios for development of CIN2+ were 10.44 (95% CI: 6.96-15.65), 9.65 (5.97-15.60), 5.68 (3.50-9.21), 5.38 (2.87-10.06) and 3.87 (2.38-6.30) for HPV-16, HPV-33, HPV-31, HPV-45 and HPV-18, respectively. HPV-16 or HPV-33 6MPIs had ~25-fold higher risk for progression to CIN3+. Previous or concomitant HPV infection or CIN1+ associated with a different HPV type increased risk. Of the different oncogenic HPV types, HPV-16 and HPV-31 infections were least likely to clear.
  
  
  CONCLUSIONS
  Cervical infections with oncogenic HPV types increased the risk of CIN2+ and CIN3+. Previous or concomitant infection or CIN1+ also increased the risk. HPV-16 and HPV-33 have by far the highest risk of progression to CIN3+, and HPV-16 and HPV-31 have the lowest chance of clearance.
authors.affiliation: Department of Obstetrics and Gynaecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
authors.forename: Unnop
authors.initials: U
authors.lastname: Jaisamrarn
authors.forename: Xavier
authors.initials: X
authors.lastname: Castellsagué
authors.forename: Suzanne M
authors.initials: SM
authors.lastname: Garland
authors.forename: Paulo
authors.initials: P
authors.lastname: Naud
authors.forename: Johanna
authors.initials: J
authors.lastname: Palmroth
authors.forename: Maria Rowena
authors.initials: MR
authors.lastname: Del Rosario-Raymundo
authors.forename: Cosette M
authors.initials: CM
authors.lastname: Wheeler
authors.forename: Jorge
authors.initials: J
authors.lastname: Salmerón
authors.forename: Song-Nan
authors.initials: SN
authors.lastname: Chow
authors.forename: Dan
authors.initials: D
authors.lastname: Apter
authors.forename: Julio C
authors.initials: JC
authors.lastname: Teixeira
authors.forename: S Rachel
authors.initials: SR
authors.lastname: Skinner
authors.forename: James
authors.initials: J
authors.lastname: Hedrick
authors.forename: Anne
authors.initials: A
authors.lastname: Szarewski
authors.forename: Barbara
authors.initials: B
authors.lastname: Romanowski
authors.forename: Fred Y
authors.initials: FY
authors.lastname: Aoki
authors.forename: Tino F
authors.initials: TF
authors.lastname: Schwarz
authors.forename: Willy A J
authors.initials: WA
authors.lastname: Poppe
authors.forename: F Xavier
authors.initials: FX
authors.lastname: Bosch
authors.forename: Newton S
authors.initials: NS
authors.lastname: de Carvalho
authors.forename: Maria Julieta
authors.initials: MJ
authors.lastname: Germar
authors.forename: Klaus
authors.initials: K
authors.lastname: Peters
authors.forename: Jorma
authors.initials: J
authors.lastname: Paavonen
authors.forename: Marie-Cecile
authors.initials: MC
authors.lastname: Bozonnat
authors.forename: Dominique
authors.initials: D
authors.lastname: Descamps
authors.forename: Frank
authors.initials: F
authors.lastname: Struyf
authors.forename: Gary O
authors.initials: GO
authors.lastname: Dubin
authors.forename: Dominique
authors.initials: D
authors.lastname: Rosillon
authors.forename: Laurence
authors.initials: L
authors.lastname: Baril
mesh_terms: D000293:Adolescent; D000328:Adult; D052685:Alphapapillomavirus; D002584:Cervix Uteri / Q000378:metabolism / Q000473:pathology / Q000821:virology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000378:metabolism* / Q000473:pathology; D012307:Risk Factors; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000378:metabolism* / Q000473:pathology / Q000821:virology*